Celgene Corp. — Sponsor Intelligence | 54 EU Trials

Filter these 54 trials by condition, phase, country and more.

Open in Search →

54 Registered trials

13 Recruiting

40 Completed trials

23 Countries active

73 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase III: 19 Phase II/III: 3 Phase II: 11 Phase I/II: 6 Phase I: 6 Phase I (Other): 9

Oversight events:

23 temporary halts 1 urgent safety measure 5 unexpected events 2 corrective measures across 11 trials

View oversight register →

100%

40 of 40 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Diffuse large B-cell lymphoma 4 Myelofibrosis 3 Marginal zone lymphoma 2 Acute myeloid leukaemia 2 Crohn's disease 2 Myelodysplastic syndrome 2 Systemic lupus erythematosus 2 Multiple sclerosis 2 Primary myelofibrosis 2 Follicular lymphoma 1 Glioblastoma 1 Non-small cell lung cancer 1

Top IMPs

DEXAMETHASONE 7 LUSPATERCEPT 7 MEZIGDOMIDE 7 DARATUMUMAB 5 AZACITIDINE 4 CARFILZOMIB 4 GOLCADOMIDE 4 IDECABTAGENE VICLEUCEL 4 BORTEZOMIB 3 IBERDOMIDE 3 LENALIDOMIDE 3 POMALIDOMIDE 3

All trials — page 2

54 total

A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended

2023-507890-17-00 Phase III 12 countries LUSPATERCEPT; SODIUM CHLORIDE
CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel… Ended

2023-505219-19-00 Phase I/II 6 countries BORTEZOMIB; CARFILZOMIB; DARATUMUMAB; DEXAMETHASONE; ELOTUZUMAB; MEZIGDOMIDE
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety of Luspatercept in subjects who have participated in other L… Ended

2022-502498-40-00 Phase III 8 countries LUSPATERCEPT
A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter… Ended

2022-501485-22-00 Phase III 14 countries EPOETIN ALFA; LUSPATERCEPT
A clinical trial to evaluate the safety and effectiveness of a combination of either AG-12or AG-221 tablets with azacitidine injections in p… Ended

2024-511722-31-00 Phase I/II 4 countries AZACITIDINE; ENASIDENIB MESILATE; IVOSIDENIB
A study to decide what is the highest dose of CC-220 to take alone and with other standard of care treatments to assess the side effects, ef… Ended

2024-510799-19-00 Phase I/II 5 countries DARATUMUMAB; DEXAMETHASONE; DEXAMETHASONE PH. EUR.; IBERDOMIDE
Study of CC-97540 (BMS-986353), CD19-CAR T Cells, in Participants with Active SLE Despite Immunosuppressants (Breakfree-SLE) Halted

2024-519278-37-00 Phase II 9 countries CC-97540
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2) Halted

2023-507820-22-00 Phase I (Other) 4 countries
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1) Halted

2023-503823-24-01 Phase I (Other) 5 countries
A Study to Evaluate CC-486 in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Cancer Partic… Ended

2023-503427-26-00 Phase I (Other) 2 countries
A Phase 1 Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors Ended

2022-500930-27-00 Phase I (Other) 3 countries
CC-122 Rollover Study Ended

2022-501855-97-00 Phase I (Other) 2 countries
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod in Pediatric Participants with Moderately to Severely Active Crohn… Ended

2023-508777-91-00 Phase II/III 6 countries OZANIMOD; OZANIMOD, OZANIMOD
"A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJ… Ended

2023-506278-10-00 Phase III 7 countries CENDAKIMAB
A Phase 1, Dose Finding Study of CC-92328 in Subjects with Relapsed and/or Refractory Multiple Myeloma. Ended

2023-505079-65-00 Phase I 1 country
A study testing increasing amounts (doses) of CC-91633 to find out what dose can be tolerated without serious side effects in patients with … Ended

2023-503869-34-00 Phase I 1 country
A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelody… Ended

2023-506117-22-00 Phase I (Other) 5 countries
A Dose Finding Phase 1 Study of CC-96191 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia Ended

2022-500573-13-00 Phase I 1 country
Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery Ended

2024-511171-15-00 Phase I (Other) 6 countries
A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi… Ended

2024-511972-33-00 Phase III 10 countries
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended

2023-509848-10-00 Phase III 7 countries BORTEZOMIB; CARFILZOMIB; DARATUMUMAB; DEXAMETHASONE; DEXAMETHASONE PH. EUR.; IDE…
A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on… Ended

2023-509800-14-00 Phase I (Other) 2 countries
A study to assess the efficacy and safety of bb2121 in people who have Myeloma that is not responsive after treatment or who had Myeloma whi… Ended

2023-505183-10-00 Phase II 3 countries IDECABTAGENE VICLEUCEL
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended

2023-510426-33-00 Phase III 14 countries OZANIMOD

Showing 25–48 of 54 trials

← All sponsors A–Z